Anixa Biosciences ANIX
NASDAQ ANIX
$2.78 +0.07 (+2.58%)
At close: Oct 22, 2026 · 4:00 PM EDT

Anixa Biosciences (ANIX) Receivables - Other (2013)

Updated

Anixa Biosciences (ANIX) reported Receivables - Other of $2,000 for fiscal Q2 2013 (quarter ended Apr 30, 2013), unchanged from the prior quarter.

Analysis

Anixa Biosciences (ANIX) Receivables - Other (2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn
10 Anixa Biosciences 96.15 Mn 81.01 Mn -
Historic Data

Historic Data

Download Data
DateValue
Apr 30, 2013 2,000.00
Jan 31, 2013 2,000.00
API Access

Anixa Biosciences Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=ANIX&period=max&api_key=YOUR_API_KEY